Cargando…
ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
The combined effect of the chemotherapeutic agent ICRF-159 and radiation on the proliferative status of tumor/normal systems has been evaluated using the Lewis lung tumour in BDF1 mice. We have previously shown that a 25 mg/kg dose of ICRF-159, given at 3h intervals X4 before irradiation, significan...
Autores principales: | Kovacs, C. J., Evans, M. J., Burholt, D. R., Schenken, L. L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1979
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009893/ https://www.ncbi.nlm.nih.gov/pubmed/486308 |
Ejemplares similares
-
ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
por: Kovacs, C. J., et al.
Publicado: (1979) -
in vitro effects of ICRF 159.
por: Hellmann, K., et al.
Publicado: (1973) -
Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
por: Davies, S. L., et al.
Publicado: (1997) -
Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.
por: Taylor, I. W., et al.
Publicado: (1977) -
The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
por: Albanese, R., et al.
Publicado: (1985)